MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application...
19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
SUZHOU, China, May 7, 2026 /PRNewswire/ -- Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP...
MOREH Demonstrates Production-Ready LLM Inference on Tenstorrent Galaxy, Achieving DGX A100-Class Performance with Improved Cost Efficiency
Reduces HBM Costs with GPU–Tenstorrent Heterogeneous Distributed Serving First unveiled at Tenstorrent's launch event, TT-Deploy, in San Francisco on May 1 SANTA CLARA, Calif., May 2, 2026 /PRNewswire/ -- Moreh, an AI infrastructure software...
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D , 600 mg QD). Phase 2 clinical outcomes include: 2L+ KRAS G12Ci–naive NSCLC: ORR of 58.8%, mPFS of 12.2 months 2L+ colorectal cancer...
Wondershare Demonstrates AI-Powered Document Workflows with PDFelement at Microsoft AI Tour Hong Kong
HONG KONG, April 23, 2026 /PRNewswire/ -- Wondershare, a global leader in digital productivity and creativity software, showcased its latest AI-powered solutions at the Microsoft AI Tour Hong Kong, highlighting how its flagship product, Wondershare...
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
HONG KONG, April 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in...
Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99% WOBURN, Mass., April 13, 2026 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology and...
10 Years After AlphaGo, Lee Sedol Returns to Launch the Era of Agentic AI
- Go grandmaster demonstrates the future of human and AI collaboration at the site of the historic AlphaGo match as Enhans unveils its multi agent AI OS SEOUL, South Korea, March 9, 2026 /PRNewswire/ -- Enhans, an enterprise Agentic AI company led...
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive...
Corporates Pledge Support of Clean Energy Goals in South Korea
High-Level Dialogue Demonstrates Shared Commitment Between Government, Corporates SEOUL, South Korea, Feb. 11, 2026 /PRNewswire/ -- This week, the Clean Energy Buyers Association (CEBA) was pleased to cohost "Renewable Energy in the Republic of...